Appropriateness of inpatient intravenous iron therapy in a Swiss tertiary care hospital

Eur J Haematol. 2023 Oct;111(4):601-610. doi: 10.1111/ejh.14053. Epub 2023 Jul 24.

Abstract

Introduction: Intravenous (IV) iron replacement is an established treatment for iron deficiency and is recommended in various medical guidelines, but cheaper oral iron formulations remain first-line therapy in several instances. Data on adherence to current prescription standards are lacking in Switzerland.

Methods: Retrospective single center quality control study evaluating the appropriateness of IV iron replacement in 400 inpatients during 2019 and 2021 at a Swiss tertiary care hospital. Appropriateness of IV iron was assessed by expert chart review according to national and international guidelines.

Results: IV iron prescriptions were assessed as inappropriate in 147 (37%) of cases (indication lacking in 13%, oral route preferred in 24%). Inappropriate prescribing was more common (p < .001) in surgical wards (66%) compared to medical units (48%) and the gynecologic ward (19%). Iron studies were lacking in 29% of inappropriate IV administrations. Insufficient replacement dosages were chosen in 38% of patients with appropriate prescription.

Conclusion: Based on current guidelines, inappropriate in-hospital prescription of IV iron was frequently observed. Considerable differences exist between hospital units, which are consistent with conflicting recommendations of professional societies. We recommend increased attention toward the prescription quality to avoid unnecessary, expensive, and potentially harmful use of IV iron.

Keywords: anemia; ferric carboxymaltose; intravenous; iron deficiency; quality control.

MeSH terms

  • Administration, Intravenous
  • Anemia, Iron-Deficiency* / drug therapy
  • Female
  • Humans
  • Inpatients
  • Iron
  • Retrospective Studies
  • Switzerland
  • Tertiary Care Centers

Substances

  • Iron